Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

The Burrill Report Interview with Jim Greenwood

The Burrill Report’s Daniel Levine spoke with Jim Greenwood, president and CEO of BIO, about the upcoming Eighth Annual BIO Investor Forum’s opening plenary session on healthcare reform. Greenwood will be moderating the session, “Healthcare Reform: Sustaining Biotech Innovation in a New World.” Listen to the podcast.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Development continues for osteoporosis drug

Osteologix, Inc. (OLGX.OB) will continue the clinical development for its osteoporosis drug, NB S101 (strontium malonate), in the U.S. and worldwide. Additionally, the company wants to recognize World Osteoporosis Day’s significance and make more people aware of its research dedicated to improving the lives of people with osteoporosis. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Oncolytics invests in private biotech company

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) invested in British Canadian Biosciences Corp., a privately held biotechnology company specializing in the development of peptides for the treatment of a variety of conditions, including cancer. Oncolytics has purchased all of the convertible preferred shares of BCBC in exchange for 200,000 common shares of Oncolytics. If converted to common shares, Oncolytics would own 10% of the outstanding BCBC common shares. In addition, Oncolytics has obtained a right, Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Podcast with Fast Forward’s Tim Coetzee

Biotech Now’s Tracy Krughoff spoke with Dr. Tim Coetzee, president of Fast Forward, a subsidiary of the National Multiple Sclerosis Society. Fast Forward will be one of the advocacy organizations presenting at the Eighth Annual BIO Investor Forum. Listen now! http://www.bio.org/podcasts/coetzee.wma

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Q&A with Complete Genomics’ Dr. Clifford Reid

Read a recent interview with Complete Genomics Chairman, President, and CEO Clifford Reid about his company’s top priorities, what makes his company attractive to investors, and what he hopes to accomplish at the 8th Annual BIO Investor Forum.  Complete Genomics sequenced its first genome in early 2009 and that data is publically available in the National Center for Biotechnology Information (NCBI) database. Already, in 2009, Complete Genomics has sequenced and delivered genomes to important collaborators Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,